Shaily Engineering Plastics Posts Strong FY26 Growth

Net profit rose to ₹169.91 Cr from ₹93.11 Cr in the previous year.
Consolidated revenue grew 25.91% to reach ₹990.67 Cr for FY26.

Reader Takeaway: Healthcare vertical momentum and margin expansion drive earnings, though consumer electronics demand remains subdued globally.

What just happened

Shaily Engineering Plastics delivered robust financial results for FY26, marked by a 630 basis point expansion in EBITDA margins to 29.04%. The company’s focus on high-value healthcare products, particularly pen injectors, has significantly improved profitability and return on capital employed (RoCE), which climbed to 35.8% from 24.4% a year earlier. To support future growth, the board has approved an enabling resolution to raise up to ₹500 Cr.

Why this matters

The company is successfully transitioning from a heavy capacity-building phase to a monetization cycle. A major milestone was the commissioning of a 25 million-unit pen injector line in March 2026, supported by a ₹423 Cr order book spanning four years. Simultaneously, Shaily is diversifying into the semiconductor space through a partnership with a Korean firm for conductive chip trays, aiming to capitalize on high-tech manufacturing demand.

Risks to watch

While healthcare is thriving, the company reported stagnant revenue in its consumer segment at ₹511.3 Cr, citing global demand softness. Furthermore, the lead time to commission new manufacturing lines has extended to 18-24 months due to increased equipment complexity, which may impact the speed of future capacity ramp-ups.

What to track next

Investors should monitor the revenue contribution from the healthcare vertical, which management expects to cross 50% of total revenue in the medium term. The timeline for the commercial supply of semiconductor components, slated for Q4 FY27, will also be a key indicator of the company’s diversification success.